VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $3.85 Million Investment in Charles River Laboratories International, Inc. $CRL

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 17,000 shares of the medical research company’s stock, valued at approximately $3,855,000.

A number of other hedge funds have also recently made changes to their positions in the company. Handelsbanken Fonder AB grew its position in Charles River Laboratories International by 36.9% during the second quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock worth $4,378,000 after buying an additional 5,200 shares in the last quarter. Avidity Partners Management LP purchased a new position in shares of Charles River Laboratories International during the first quarter worth about $1,670,000. Maverick Capital Ltd. purchased a new position in shares of Charles River Laboratories International during the first quarter worth about $1,411,000. California State Teachers Retirement System increased its position in shares of Charles River Laboratories International by 21.8% in the first quarter. California State Teachers Retirement System now owns 56,972 shares of the medical research company’s stock worth $9,828,000 after purchasing an additional 10,207 shares during the last quarter. Finally, Clearbridge Investments LLC raised its stake in Charles River Laboratories International by 23.0% in the fourth quarter. Clearbridge Investments LLC now owns 511,618 shares of the medical research company’s stock valued at $102,058,000 after purchasing an additional 95,619 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Down 0.9%

Shares of CRL opened at $278.36 on Thursday. The firm has a market cap of $13.29 billion, a price-to-earnings ratio of -57.39, a PEG ratio of 2.75 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $303.30. The firm has a 50 day moving average price of $258.38 and a 200-day moving average price of $204.34.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter in the prior year, the company earned $3.12 EPS. The firm’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the transaction, the director owned 1,438 shares in the company, valued at approximately $410,175.12. The trade was a 28.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Victoria L. Creamer sold 4,179 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the completion of the sale, the executive vice president directly owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This trade represents a 12.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 165,990 shares of company stock valued at $42,606,388. 1.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Barclays reiterated an “overweight” rating and set a $300.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. TD Cowen increased their target price on Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Royal Bank Of Canada raised their price target on Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Finally, Piper Sandler set a $300.00 price target on Charles River Laboratories International in a research note on Monday, August 10th. Eleven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $259.44.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.